Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarek Sahmoud

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The Lancet. Infectious Diseases|May 1, 2020
Estimation of COVID-19 burden in EgyptTarek Sahmoud
Clinical Breast Cancer|May 4, 2005
Current and future perspectives on fulvestrantWilliam J Gradishar, Tarek Sahmoud
Annals of the New York Academy of Sciences|May 11, 2013
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseasesDavid Lebwohl, Ozlem Anak, Tarek Sahmoud, et al.
Breast Cancer Research and Treatment|November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerGuy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2010
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumabFabrice Andre, Mario Campone, Ruth O'Regan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2011
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issuesCharles Ferté, Angelo Paci, Meriem Zizi, et al.
The New England Journal of Medicine|November 5, 2010
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosisDarcy A Krueger, Marguerite M Care, Katherine Holland, et al.
Plos One|January 10, 2013
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
Plos One|April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast CancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
Lancet (London, England)|January 15, 2013
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialJohn J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Lancet. Infectious Diseases|May 1, 2020
Estimation of COVID-19 burden in EgyptTarek Sahmoud
Clinical Breast Cancer|May 4, 2005
Current and future perspectives on fulvestrantWilliam J Gradishar, Tarek Sahmoud
Annals of the New York Academy of Sciences|May 11, 2013
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseasesDavid Lebwohl, Ozlem Anak, Tarek Sahmoud, et al.
Breast Cancer Research and Treatment|November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerGuy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2010
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumabFabrice Andre, Mario Campone, Ruth O'Regan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2011
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issuesCharles Ferté, Angelo Paci, Meriem Zizi, et al.
The New England Journal of Medicine|November 5, 2010
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosisDarcy A Krueger, Marguerite M Care, Katherine Holland, et al.
Plos One|January 10, 2013
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
Plos One|April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast CancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
Lancet (London, England)|January 15, 2013
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialJohn J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, et al.
Pageof 3